Structure Therapeutics (NASDAQ:GPCR) Trading Up 10.5% – What’s Next?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price was up 10.5% on Thursday . The company traded as high as $41.86 and last traded at $41.82. Approximately 735,788 shares were traded during trading, a decline of 5% from the average daily volume of 775,766 shares. The stock had previously closed at $37.86.

Analysts Set New Price Targets

A number of equities analysts have weighed in on GPCR shares. Morgan Stanley began coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. JMP Securities lowered their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $86.80.

Structure Therapeutics Price Performance

The firm’s 50 day moving average is $39.50 and its 200 day moving average is $39.73. The firm has a market cap of $2.35 billion, a P/E ratio of -55.57 and a beta of -3.53.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. As a group, analysts expect that Structure Therapeutics Inc. will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GPCR. Sandia Investment Management LP purchased a new position in Structure Therapeutics in the second quarter worth about $39,000. Quarry LP purchased a new position in shares of Structure Therapeutics during the second quarter valued at approximately $79,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after purchasing an additional 1,420 shares during the last quarter. Bank Pictet & Cie Europe AG purchased a new position in shares of Structure Therapeutics during the third quarter valued at approximately $206,000. Finally, Sei Investments Co. purchased a new position in shares of Structure Therapeutics during the second quarter valued at approximately $212,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.